973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
M. Garassino, S. Gadgeel, G. Speranza, E. Felip +16 more
2022Annals of Oncology26 citations Open access
Semantic Scholar

